U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C23H27Cl2N3O2
Molecular Weight 448.385
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ARIPIPRAZOLE

SMILES

ClC1=C(Cl)C(=CC=C1)N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2

InChI

InChIKey=CEUORZQYGODEFX-UHFFFAOYSA-N
InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)

HIDE SMILES / InChI
Molecular Formula C23H27Cl2N3O2
Molecular Weight 448.385
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12784105/, https://www.ncbi.nlm.nih.gov/pubmed/12587943, https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0000157/

Aripiprazole is the first next-generation atypical antipsychotic. The unique actions of aripiprazole in humans are likely a combination of "functionally selective" activation of D(2) (and possibly D(3))-dopamine receptors and serotonin 5-HT(1A) receptors, coupled with inhibition of 5-HT(2A) receptors. Aripiprazole was approved by FDA (Abilify trade name) for the treatment of schizophrenia; manic and mixed episodes associated with bipolar I disorder; major depressive disorder; irritability associated with autistic disorder; Tourette’s disorder and agitation associated with schizophrenia or bipolar mania.

CNS Activity

Originator

Approval Year

2002
144
Targets

Targets

Primary TargetPharmacologyConditionPotency
Partial Agonist
297
 0.34 nM [Ki]
Antagonist
2849
 8.7 nM [Ki]
Partial Agonist
297
 5.6 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
ABILIFY

Approved Use

ABILIFY is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia, Acute Treatment of Manic and Mixed Episodes associated with Bipolar I, Adjunctive Treatment of Major Depressive Disorder, Irritability Associated with Autistic Disorder, Treatment of Tourette’s disorder, The injection is indicated for: Agitation associated with schizophrenia or bipolar mania

Launch Date

2002
Primary
Approved
8583
ABILIFY

Approved Use

ABILIFY is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia, Acute Treatment of Manic and Mixed Episodes associated with Bipolar I, Adjunctive Treatment of Major Depressive Disorder, Irritability Associated with Autistic Disorder, Treatment of Tourette’s disorder, The injection is indicated for: Agitation associated with schizophrenia or bipolar mania

Launch Date

2002
Primary
Approved
8583
ABILIFY

Approved Use

ABILIFY is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia, Acute Treatment of Manic and Mixed Episodes associated with Bipolar I, Adjunctive Treatment of Major Depressive Disorder, Irritability Associated with Autistic Disorder, Treatment of Tourette’s disorder, The injection is indicated for: Agitation associated with schizophrenia or bipolar mania

Launch Date

2002
Primary
Approved
8583
ABILIFY

Approved Use

ABILIFY is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia, Acute Treatment of Manic and Mixed Episodes associated with Bipolar I, Adjunctive Treatment of Major Depressive Disorder, Irritability Associated with Autistic Disorder, Treatment of Tourette’s disorder, The injection is indicated for: Agitation associated with schizophrenia or bipolar mania

Launch Date

2002
Primary
Approved
8583
ABILIFY

Approved Use

ABILIFY is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia, Acute Treatment of Manic and Mixed Episodes associated with Bipolar I, Adjunctive Treatment of Major Depressive Disorder, Irritability Associated with Autistic Disorder, Treatment of Tourette’s disorder, The injection is indicated for: Agitation associated with schizophrenia or bipolar mania

Launch Date

2002
Primary
Approved
8583
ABILIFY

Approved Use

ABILIFY is an atypical antipsychotic indicated as oral formulations for the: Treatment of schizophrenia (1.1) Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in patients with schizophrenia (14.1) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (1.2) Adults: Efficacy was established in four 3-week monotherapy trials and one 6-week adjunctive trial in patients with manic or mixed episodes (14.2) Pediatric Patients (ages 10-17): Efficacy was established in one 4-week monotherapy trial in patients with manic or mixed episodes (14.2) Maintenance treatment of bipolar I disorder, both as monotherapy and as an adjunct to lithium or valproate (1.2) Adults: Efficacy was established in one maintenance monotherapy trial and in one maintenance adjunctive trial (14.2) Adjunctive treatment of major depressive disorder (MDD) (1.3) Adults: Efficacy was established in two 6-week trials in patients with MDD who had an inadequate response to antidepressant therapy during the current episode (14.3) Treatment of irritability associated with autistic disorder (1.4) Pediatric Patients (ages 6-17 years): Efficacy was established in two 8-week trials in patients with autistic disorder (14.4) as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (1.5) Adults: Efficacy was established in three 24-hour trials in agitated patients with schizophrenia or manic/mixed episodes of bipolar I disorder (14.5) 1.1 Schizophrenia ABILIFY is indicated for the treatment of schizophrenia. The efficacy of ABILIFY was established in four 4-6 week trials in adults and one 6-week trial in adolescents (13 to 17 years). Maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents [see CLINICAL STUDIES (14.1)

Launch Date

2002
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
163 ng/mL
REVIEW
https://www.ncbi.nlm.nih.gov/pubmed/15257633
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARIPIPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2947 ng × h/mL
REVIEW
https://www.ncbi.nlm.nih.gov/pubmed/15257633
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARIPIPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
52.9 h
REVIEW
https://www.ncbi.nlm.nih.gov/pubmed/15257633
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARIPIPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
REVIEW
https://www.ncbi.nlm.nih.gov/pubmed/15257633
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARIPIPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18626272
unhealthy, 10-17 years
Health Status: unhealthy
Age Group: 10-17 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18626272
Other AEs: Abdominal pain upper, Vomiting...
Other AEs:
Abdominal pain upper (17%)
Vomiting (17%)
Dizziness (17%)
Headache (50%)
Sedation (33%)
Somnolence (17%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18626272
2 mg single, intravenous
Dose: 2 mg
Route: intravenous
Route: single
Dose: 2 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/18563956/
healthy, 35 years (range: 18-45 years)
Health Status: healthy
Age Group: 35 years (range: 18-45 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18563956/
Sources:
https://pubmed.ncbi.nlm.nih.gov/18563956/
45 mg single, intramuscular
Highest studied dose
Dose: 45 mg
Route: intramuscular
Route: single
Dose: 45 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/18563956/
unhealthy, 39 years (range: 18-65 years)
Health Status: unhealthy
Age Group: 39 years (range: 18-65 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18563956/
Sources:
https://pubmed.ncbi.nlm.nih.gov/18563956/
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Other AEs: Vomiting, Somnolence...
Other AEs:
Vomiting
Somnolence
Tremor
Acidosis
Aggression
Aspartate aminotransferase increased
Atrial fibrillation
Coma
Confusional state
Convulsion
Blood creatine phosphokinase increased
Depressed level of consciousness
Hypertension
Hypokalemia
Hypotension
Lethargy
Loss of consciousness
QT prolonged
Aspiration pneumonia
Respiratory arrest
Status epilepticus
Tachycardia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Other AEs: Extrapyramidal disorder, Neuroleptic malignant syndrome...
Other AEs:
Extrapyramidal disorder (serious, 1 patient)
Neuroleptic malignant syndrome (serious, 1 patient)
Aggression (serious, 1 patient)
Schizophrenia (serious, 1 patient)
Nausea (below serious, 9 patients)
Nasopharyngitis (below serious, 5 patients)
Dizziness (below serious, 7 patients)
Extrapyramidal disorder (below serious, 13 patients)
Headache (below serious, 16 patients)
Somnolence (below serious, 11 patient)
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Other AEs: Varicella, Depression...
Other AEs:
Varicella (serious, 1 patient)
Depression (serious, 1 patient)
Schizophrenia (serious, 1 patient)
Suicidal ideation (serious, 1 patient)
Thrombophlebitis (serious, 1 patient)
Nausea (below serious, 10 patients)
Nasopharyngitis (below serious, 5 patients)
Dizziness (below serious, 4 patients)
Extrapyramidal disorder (below serious, 22 patients)
Headache (below serious, 11 patient)
Somnolence (below serious, 22 patients)
Tremor (below serious, 12 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Other AEs: Vomiting, Somnolence...
Other AEs:
Vomiting
Somnolence
Tremor
Acidosis
Aggression
Aspartate aminotransferase increased
Atrial fibrillation
Coma
Confusional state
Convulsion
Blood creatine phosphokinase increased
Depressed level of consciousness
Hypertension
Hypokalemia
Hypotension
Lethargy
Loss of consciousness
QT prolonged
Aspiration pneumonia
Respiratory arrest
Status epilepticus
Tachycardia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Other AEs: Adverse event...
Other AEs:
Adverse event (grade 5)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Other AEs: Constipation, Diarrhea...
Other AEs:
Constipation (below serious, 8 patients)
Diarrhea (below serious, 7 patients)
Nausea (below serious, 2 patients)
Abdominal discomfort (below serious, 7 patients)
Vomiting (below serious, 15 patients)
Decreased appetite (below serious, 12 patients)
Increased appetite (below serious, 16 patients)
Drowsiness (below serious, 5 patients)
Tiredness (below serious, 21 patient)
Fever (below serious, 3 patients)
Weight gain (below serious, 8 patients)
Muscle rigidity (below serious, 3 patients)
Tremor (below serious, 3 patients)
Nervousness (below serious, 3 patients)
Repetitive speech (below serious, 3 patients)
Restlessness (below serious, 3 patients)
Feeling sad (below serious, 3 patients)
Self injurious behavior (below serious, 3 patients)
Enuresis (below serious, 3 patients)
Dizziness (below serious, 4 patients)
Nose bleed (below serious, 3 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Other AEs: Abdominal pain, Bruising...
Other AEs:
Abdominal pain (below serious, 7 patients)
Bruising (below serious, 2 patients)
Constipation (below serious, 6 patients)
Diarrhea (below serious, 9 patients)
Dizziness (below serious, 5 patients)
Dry mouth (below serious, 6 patients)
Enuresis (below serious, 5 patients)
Headache (below serious, 6 patients)
Insomnia (below serious, 8 patients)
Malaise (below serious, 7 patients)
Mucosal ulceration (below serious, 4 patients)
Nausea (below serious, 10 patients)
Restlessness (below serious, 5 patients)
Sedation (below serious, 7 patients)
Tinnitus (below serious, 7 patients)
Tremor (below serious, 8 patients)
Vomiting (below serious, 10 patients)
Weight loss (below serious, 4 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
Other AEs: Restlessness, Decreased activity...
Other AEs:
Restlessness (below serious, 2 patients)
Decreased activity (below serious, 1 patient)
Drowsiness (below serious, 2 patients)
Vertigo (below serious, 1 patient)
Cold extremities (below serious, 1 patient)
Blurred vision (below serious, 2 patients)
Sexual disorder NOS (below serious, 2 patients)
Joint stiffness (below serious, 1 patient)
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
Other AEs: Rhabdomyolysis, Pneumonia...
Other AEs:
Rhabdomyolysis (serious, 1 patient)
Pneumonia (serious, 1 patient)
Cellulitis (serious, 1 patient)
Abrasions (below serious, 3 patients)
Akathisia (below serious, 12 patients)
Drowsiness (below serious, 6 patients)
Fatigue (below serious, 8 patients)
Depressed mood (below serious, 3 patients)
Hypernatremia (below serious, 4 patients)
Hypocalcemia (below serious, 3 patients)
ALT increased (below serious, 8 patients)
Aspartate aminotransferase increased (below serious, 6 patients)
Restlessness (below serious, 4 patients)
Sleep disturbance (below serious, 3 patients)
Infection upper respiratory (below serious, 6 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
Other AEs: Suicidal ideation, Gun shot wound...
Other AEs:
Suicidal ideation (serious, 2 patients)
Gun shot wound (serious, 1 patient)
Injury (serious, 1 patient)
Multiple injuries (serious, 1 patient)
Diabetes mellitus (serious, 1 patient)
Hyperglycaemia (serious, 1 patient)
Pancreatic carcinoma (serious, 1 patient)
Hallucination, auditory (serious, 1 patient)
Suicide attempt (serious, 1 patient)
Headache (below serious, 16 patients)
Insomnia (below serious, 27 patients)
Tremor (below serious, 16 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
AEs

AEs

AESignificanceDosePopulation
Abdominal pain upper 17%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18626272
unhealthy, 10-17 years
Health Status: unhealthy
Age Group: 10-17 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18626272
Dizziness 17%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18626272
unhealthy, 10-17 years
Health Status: unhealthy
Age Group: 10-17 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18626272
Somnolence 17%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18626272
unhealthy, 10-17 years
Health Status: unhealthy
Age Group: 10-17 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18626272
Vomiting 17%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18626272
unhealthy, 10-17 years
Health Status: unhealthy
Age Group: 10-17 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18626272
Sedation 33%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18626272
unhealthy, 10-17 years
Health Status: unhealthy
Age Group: 10-17 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18626272
Headache 50%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18626272
unhealthy, 10-17 years
Health Status: unhealthy
Age Group: 10-17 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18626272
Acidosis
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Aggression
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Aspartate aminotransferase increased
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Aspiration pneumonia
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Atrial fibrillation
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Blood creatine phosphokinase increased
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Coma
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Confusional state
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Convulsion
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Depressed level of consciousness
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Hypertension
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Hypokalemia
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Hypotension
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Lethargy
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Loss of consciousness
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
QT prolonged
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Respiratory arrest
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Somnolence
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Status epilepticus
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Tachycardia
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Tremor
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Vomiting
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, < 12 years
Health Status: unhealthy
Age Group: < 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Somnolence below serious, 11 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Extrapyramidal disorder below serious, 13 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Headache below serious, 16 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Nasopharyngitis below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Dizziness below serious, 7 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Nausea below serious, 9 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Aggression serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Extrapyramidal disorder serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Neuroleptic malignant syndrome serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Schizophrenia serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Nausea below serious, 10 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Headache below serious, 11 patient
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Tremor below serious, 12 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Extrapyramidal disorder below serious, 22 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Somnolence below serious, 22 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Dizziness below serious, 4 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Nasopharyngitis below serious, 5 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Depression serious, 1 patient
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Schizophrenia serious, 1 patient
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Suicidal ideation serious, 1 patient
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Thrombophlebitis serious, 1 patient
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Varicella serious, 1 patient
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
unhealthy, adolescent
Health Status: unhealthy
Age Group: adolescent
Sources:
https://clinicaltrials.gov/ct2/show/NCT00102063
Acidosis
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Aggression
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Aspartate aminotransferase increased
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Aspiration pneumonia
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Atrial fibrillation
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Blood creatine phosphokinase increased
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Coma
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Confusional state
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Convulsion
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Depressed level of consciousness
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Hypertension
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Hypokalemia
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Hypotension
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Lethargy
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Loss of consciousness
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
QT prolonged
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Respiratory arrest
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Somnolence
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Status epilepticus
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Tachycardia
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Tremor
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Vomiting
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Adverse event grade 5
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf
Decreased appetite below serious, 12 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Vomiting below serious, 15 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Increased appetite below serious, 16 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Nausea below serious, 2 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Tiredness below serious, 21 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Enuresis below serious, 3 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Feeling sad below serious, 3 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Fever below serious, 3 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Muscle rigidity below serious, 3 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Nervousness below serious, 3 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Nose bleed below serious, 3 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Repetitive speech below serious, 3 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Restlessness below serious, 3 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Self injurious behavior below serious, 3 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Tremor below serious, 3 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Dizziness below serious, 4 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Drowsiness below serious, 5 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Abdominal discomfort below serious, 7 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Diarrhea below serious, 7 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Constipation below serious, 8 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Weight gain below serious, 8 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT00198107
Nausea below serious, 10 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Vomiting below serious, 10 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Bruising below serious, 2 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Mucosal ulceration below serious, 4 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Weight loss below serious, 4 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Dizziness below serious, 5 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Enuresis below serious, 5 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Restlessness below serious, 5 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Constipation below serious, 6 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Dry mouth below serious, 6 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Headache below serious, 6 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Abdominal pain below serious, 7 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Malaise below serious, 7 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Sedation below serious, 7 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Tinnitus below serious, 7 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Insomnia below serious, 8 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Tremor below serious, 8 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Diarrhea below serious, 9 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
unhealthy
Health Status: unhealthy
Sex: F
Sources:
https://clinicaltrials.gov/ct2/show/NCT01338298
Cold extremities below serious, 1 patient
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
Decreased activity below serious, 1 patient
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
Joint stiffness below serious, 1 patient
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
Vertigo below serious, 1 patient
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
Blurred vision below serious, 2 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
Drowsiness below serious, 2 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
Restlessness below serious, 2 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
Sexual disorder NOS below serious, 2 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00489866
Akathisia below serious, 12 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
Abrasions below serious, 3 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
Depressed mood below serious, 3 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
Hypocalcemia below serious, 3 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
Sleep disturbance below serious, 3 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
Hypernatremia below serious, 4 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
Restlessness below serious, 4 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
Aspartate aminotransferase increased below serious, 6 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
Drowsiness below serious, 6 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
Infection upper respiratory below serious, 6 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
ALT increased below serious, 8 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
Fatigue below serious, 8 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
Cellulitis serious, 1 patient
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
Pneumonia serious, 1 patient
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
Rhabdomyolysis serious, 1 patient
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00497055
Headache below serious, 16 patients
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
Tremor below serious, 16 patients
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
Insomnia below serious, 27 patients
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
Diabetes mellitus serious, 1 patient
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
Gun shot wound serious, 1 patient
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
Hallucination, auditory serious, 1 patient
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
Hyperglycaemia serious, 1 patient
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
Injury serious, 1 patient
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
Multiple injuries serious, 1 patient
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
Pancreatic carcinoma serious, 1 patient
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
Suicide attempt serious, 1 patient
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
Suicidal ideation serious, 2 patients
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00705783
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946

inhibitor
2252
substrate
1193

inhibitor
2438
substrate
1388

inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2C19
2057

P-gp
1741

BCRP
910
CYP1A1
389

CYP1A2
1197

CYP2A6
626

CYP2B6
776

CYP2C8
810

CYP2C19
1119

CYP2E1
729

UGT
219

P-gp
2052
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C19
2141
 not significant
unlikely (co-administration study)
Comment: aripiprazole had no effect ont the PK of omeprazole
Page: 43.0
CYP2C9
2497
 not significant
unlikely (co-administration study)
Comment: aripiprazole had no effect on the PK of warfarin
Page: 43.0
CYP2D6
2546
 not significant
unlikely (co-administration study)
Comment: aripiprazole had no effect on the PK of of dextromethorphan
Page: 43.0
CYP3A4
2633
 not significant
unlikely (co-administration study)
Comment: aripiprazole had no effect on the PK of of dextromethorphan
Page: 43.0
CYP1A2
2333
 not significant
P-gp
1932
 yes [IC50 1.2 uM]
BCRP
985
 yes [IC50 3.5 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A1
389
 no
CYP1A2
1197
 no
CYP2A6
626
 no
CYP2B6
776
 no
CYP2C19
1119
 no
CYP2C8
810
 no
CYP2C9
1193
 no
CYP2E1
729
 no
UGT
219
 no
P-gp
2052
 yes
CYP2D6
1388
 yes
yes (co-administration study)
Comment: Coadministration of aripiprazole with quinidine, a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%; PHARMACOGENOMIC STUDY: 82% increase in aripiprazole systemic exposure in CYP2D6 PM compared to EM, net increase of aripiprazole exposure is greater than 60%, total body clearance of aripiprazole in PM decreased by 40%, not adequately studied in PM patients;
Page: 29.0
CYP3A4
1946
 yes
yes (co-administration study)
Comment: Coadministration of ketoconazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively; Coadministration of carbamazepine, a potent CYP3A4 inducer, resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole;
Page: 29.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:31236
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31236
ChemicalBook
CB42487193
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB42487193
ChemicalBook
CB8210870
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8210870
eMolecules
901410
https://www.emolecules.com/cgi-bin/more?vid=901410
MolPort
MolPort-002-885-808
https://www.molport.com/shop/molecule-link/MolPort-002-885-808
MolPort
MolPort-046-939-776
https://www.molport.com/shop/molecule-link/MolPort-046-939-776
Selleck Chemicals
aripiprazole-abilify
http://www.selleckchem.com/products/aripiprazole-abilify.html
ZINC
ZINC000001851149
http://zinc15.docking.org/substances/ZINC000001851149
PubMed

PubMed

TitleDatePubMed
Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes.
1999 Jun
Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology.
2000 Jan
In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol.
2001 Jun 1
Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors.
2001 Nov
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
2002
Aripiprazole. Abilitat, OPC 14597.
2002
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.
2002 Apr 26
Gateways to clinical trials.
2002 Dec
Aripiprazole (Otsuka Pharmaceutical Co).
2002 Jan
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.
2002 Jul
Partial dopamine agonists in the treatment of psychosis.
2002 Mar
Psychotropic drugs and the ECG: focus on the QTc interval.
2002 May
Similarities and differences among antipsychotics.
2003
Choice of maintenance medication for schizophrenia.
2003
New developments in the pharmacotherapy of schizophrenia.
2003
Treatment for mood and anxiety disorders: quetiapine and aripiprazole.
2003 Aug
Medication developments in the treatment of mental illness.
2003 Dec
Relationship of atypical antipsychotics with development of diabetes mellitus.
2003 Dec
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.
2003 Dec
Aripiprazole.
2003 Dec 1
Gateways to clinical trials.
2003 Jan-Feb
Characterization of the 5-HT6 receptor coupled to Ca2+ signaling using an enabling chimeric G-protein.
2003 Jul 4
Gateways to clinical trials.
2003 Jun
Aripiprazole.
2003 Jun
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
2003 Jun
Serotonin receptors: their key role in drugs to treat schizophrenia.
2003 Oct
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
2003 Sep
Dopamine partial agonists: a new class of antipsychotic.
2004
Gateways to clinical trials.
2004 Apr
Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats.
2004 Apr
The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
2004 Apr 2
Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics.
2004 Feb
Gateways to clinical trials.
2004 Jan-Feb
The case for atypical antipsychotics in bipolar disorder.
2004 Jan-Mar
Gateways to clinical trials.
2004 Mar
International Congress of Biological Psychiatry. 8-13 February 2004, Sydney, Australia.
2004 Mar
Patents

Patents

JP2007509153A
4
JP2008521835A
4
JP4178032B2
6
JP4836797B2
4
JP5300194B2
4

Sample Use Guides

In Vivo Use Guide
In adults with schizophrenia the recommended starting and target dose for aripiprazole (ABILIFY) is 10 or 15 mg/day. In adolescents the target dose is 10 mg/day. In adults with Bipolar I Disorder, the recommended starting dose is 15 mg given once daily as monotherapy and 10 mg to 15 mg given once daily as adjunctive therapy with lithium or valproate. In pediatric patients (10 to 17 years) with Bipolar I Disorder, the starting dose as monotherapy is 2 mg/day, with titration to 5 mg/day after 2 days, and a target dose of 10 mg/day after 2 additional days. In adults with Major Depressive Disorder, the recommended starting dose as adjunctive treatment for patients already taking an antidepressant is 2 to 5 mg/day. The recommended dosage range is 2 to 15 mg/day. In pediatric patients with Irritability Associated with Autistic Disorder, dosing should be initiated at 2 mg/day. The dose should be increased to 5 mg/day, with subsequent increases to 10 or 15 mg/day if needed. In pediatric patient with Tourette’s Disorder, the recommended dosage is 5 to 20 mg/day. In adults with Agitation Associated with Schizophrenia or Bipolar Mania, the recommended dose is 9.75 mg. The recommended dosage range is 5.25 to 15 mg.
Route of Administration: Other
In Vitro Use Guide
PC12 cells were treated with 0.001-1.0 uM aripiprazole in the presence of NGF (2.5ng/ml). Aripiprazole significantly potentiated nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells, in a concentration-dependent manner.
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:26:16 GMT 2025
Edited
by admin
on Mon Mar 31 21:26:16 GMT 2025
Record UNII
82VFR53I78
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ARIPIPRAZOLE
EMA EPAR   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
ABILIFY
Preferred Name English
ARIPIPRAZOLE [USAN]
Common Name English
ARIPIPRAZOLE [USP MONOGRAPH]
Common Name English
ABILIFY MYCITE
Brand Name English
ABILIFY MAINTENA
Brand Name English
OPC-14597
Code English
ARIPIPRAZOLE [MART.]
Common Name English
ARIPIPRAZOLE [HSDB]
Common Name English
OPC-31
Code English
aripiprazole [INN]
Common Name English
2(1H)-QUINOLINONE, 7-(4-(4-(2,3-DICHLOROPHENYL)-1-PIPERAZINYL)BUTOXY)-3,4-DIHYDRO-
Systematic Name English
ARIPIPREX
Brand Name English
7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril
Common Name English
NSC-759266
Code English
Aripiprazole [WHO-DD]
Common Name English
ARIPIPRAZOLE [MI]
Common Name English
ARIPIPRAZOLE [VANDF]
Common Name English
ARIPIPRAZOLE [JAN]
Common Name English
ARIPIPRAZOLE [EMA EPAR]
Common Name English
ARIPIPRAZOLE [USP-RS]
Common Name English
ARIPIPRAZOLE [EP MONOGRAPH]
Common Name English
ARIPIPRAZOLE [ORANGE BOOK]
Common Name English
ABILIFY MYCITE KIT
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C29710
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
FDA ORPHAN DRUG 207905
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
EMA ASSESSMENT REPORTS ABILIFY (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
LIVERTOX NBK547858
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
EMA ASSESSMENT REPORTS ABILIFY MAINTENA (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
WHO-ATC N05AX12
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
FDA ORPHAN DRUG 694219
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
EMA ASSESSMENT REPORTS ABILIFY (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
WHO-VATC QN05AX12
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
NDF-RT N0000175430
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
Code System Code Type Description
HSDB
7320
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
WIKIPEDIA
ARIPIPRAZOLE
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
LACTMED
Aripiprazole
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
DAILYMED
82VFR53I78
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
MERCK INDEX
m2046
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY Merck Index
CHEBI
31236
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
INN
7477
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
PUBCHEM
60795
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
EPA CompTox
DTXSID3046083
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
NCI_THESAURUS
C47403
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
DRUG BANK
DB01238
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
NSC
759266
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
IUPHAR
34
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
ChEMBL
CHEMBL1112
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
EVMPD
SUB05564MIG
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
DRUG CENTRAL
242
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
RS_ITEM_NUM
1042634
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
MESH
C094645
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
FDA UNII
82VFR53I78
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
USAN
II-87
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
RXCUI
89013
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY RxNorm
CAS
129722-12-9
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
SMS_ID
100000089957
Created by admin on Mon Mar 31 21:26:16 GMT 2025 , Edited by admin on Mon Mar 31 21:26:16 GMT 2025
PRIMARY
Related Record Type Details
D(3) DOPAMINE RECEPTOR
TARGET->PARTIAL AGONIST
Ki
5-HYDROXYTRYPTAMINE RECEPTOR 1A
TARGET->PARTIAL AGONIST
Ki
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of ARIPIPRAZOLE
EXCRETED UNCHANGED
FECAL
D(2) DOPAMINE RECEPTOR
TARGET->PARTIAL AGONIST
Ki
5-HYDROXYTRYPTAMINE RECEPTOR 1A
TARGET->PARTIAL AGONIST
Emax = 68.1% of effect of 1 micromolar of 5-HT.
EC50
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
5-HYDROXYTRYPTAMINE RECEPTOR 7
TARGET -> INHIBITOR
Ki
Structure of ARIPIPRAZOLE
EXCRETED UNCHANGED
URINE
5-HYDROXYTRYPTAMINE RECEPTOR 2A
TARGET -> INHIBITOR
5-HYDROXYTRYPTAMINE RECEPTOR 6
TARGET->LIGAND
Ki
5-HYDROXYTRYPTAMINE RECEPTOR 2B
TARGET->INVERSE AGONIST
Ki
D(2) DOPAMINE RECEPTOR
TARGET->PARTIAL AGONIST
Primary target for antipsychotic activity. The partial agonist actions of aripiprazole vary widely depending upon the cellular milieu. Thus, nearly fullagonism, weak partial agonism and frank antagonism, have all been reported, depending upon the assay system and cellular background.
Ki
5-HYDROXYTRYPTAMINE RECEPTOR 7
TARGET -> INHIBITOR
Ki
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
5-HYDROXYTRYPTAMINE RECEPTOR 2A
TARGET -> INHIBITOR
Structure of ARIPIPRAZOLE MONOHYDRATE
SOLVATE->ANHYDROUS
Structure of ARIPIPRAZOLE MONOHYDRATE
SALT/SOLVATE -> PARENT
5-HYDROXYTRYPTAMINE RECEPTOR 2A
TARGET -> INHIBITOR
Ki
Related Record Type Details
Structure of 7-(4-HYDROXYBUTOXY)-3,4-DIHYDROQUINOLIN-2(1H)-ONE
METABOLITE -> PARENT
URINE
Structure of 2,3-DICHLORO-4-PIPERAZIN-1-YL-PHENOL
METABOLITE -> PARENT
URINE
Structure of DEHYDROARIPIPRAZOLE
METABOLITE ACTIVE -> PARENT
MAJOR
PLASMA
Structure of OPC-3952
METABOLITE -> PARENT
URINE
Structure of 4-((2-OXO-3,4-DIHYDRO-1H-QUINOLIN-7-YL)OXY)BUTANOIC ACID
METABOLITE -> PARENT
N-Dealkylation metabolite thru CYP3A4 exposure.
Structure of 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-4-hydroxy-2(1H)-quinolinone
METABOLITE -> PARENT
Structure of (2,3-DICHLORO-4-(4-(4-((2-OXO-1H-QUINOLIN-7-YL)OXY)BUTYL)PIPERAZIN-1-YL)PHENYL) HYDROGEN SULFATE
METABOLITE -> PARENT
Structure of 7-(4-(4-(2,3-DICHLORO-4-HYDROXY-PHENYL)PIPERAZIN-1-YL)BUTOXY)-3,4-DIHYDRO-1H-QUINOLIN-2-ONE
METABOLITE -> PARENT
Structure of 7-(4-(4-(2,3-DICHLORO-4-HYDROXY-PHENYL)PIPERAZIN-1-YL)BUTOXY)-1H-QUINOLIN-2-ONE
METABOLITE -> PARENT
FECAL
Structure of 2(1H)-QUINOLINONE, 7-(4-(4-(2,3-DICHLORO-4-(SULFOOXY)PHENYL)-1-PIPERAZINYL)BUTOXY)-3,4-DIHYDRO-
METABOLITE -> PARENT
PLASMA
Structure of (2,3-DICHLORO-4-PIPERAZIN-1-YL-PHENYL) HYDROGEN SULFATE
METABOLITE -> PARENT
URINE
Structure of 7-(4-(4-(2,3-DICHLORO-4-HYDROXY-PHENYL)PIPERAZIN-1-YL)BUTOXY)-1H-QUINOLIN-2-ONE
METABOLITE -> PARENT
PLASMA
Structure of 1-(2,3-Dichlorophenyl)piperazine
METABOLITE -> PARENT
N-Dealkylation metabolite thru CYP3A4 exposure
Structure of .BETA.-D-GLUCOPYRANOSIDURONIC ACID, 2,3-DICHLORO-4-(4-(4-((1,2,3,4-TETRAHYDRO-2-OXO-7-QUINOLINYL)OXY)BUTYL)-1-PIPERAZINYL)PHENYL
METABOLITE -> PARENT
PLASMA
Structure of DEHYDROARIPIPRAZOLE
METABOLITE ACTIVE -> PARENT
MAJOR
FECAL
Structure of (2S,3S,4S,5R,6S)-6-(2,3-DICHLORO-4-PIPERAZIN-1-YL-PHENOXY)-3,4,5-TRIHYDROXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID
METABOLITE -> PARENT
URINE
Related Record Type Details
Structure of DESCHLORO ARIPIPRAZOLE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ARIPIPRAZOLE DIQUINOLINE BUTANEDIOL
IMPURITY -> PARENT
Structure of DESETHYLENE ARIPIPRAZOLE
IMPURITY -> PARENT
Structure of ARIPIPRAZOLE N1-OXIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 7,7'-((OXYBIS(BUTANE-4,1-DIYL))BIS(OXY))BIS(3,4-DIHYDROQUINOLIN-2(1H)-ONE)
IMPURITY -> PARENT
Structure of 2-DESCHLORO ARIPIPRAZOLE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of DEHYDROARIPIPRAZOLE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 7-(4-HYDROXYBUTOXY)-3,4-DIHYDROQUINOLIN-2(1H)-ONE
IMPURITY -> PARENT
Structure of 1-(2,3-Dichlorophenyl)piperazine
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ARIPIPRAZOLE DIMER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 7-HYDROXY-3,4-DIHYDROCARBOSTYRIL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3,4-DIHYDRO-7-(4-IODOBUTOXY)-2(1H)-QUINOLINONE
IMPURITY -> PARENT
Related Record Type Details
Structure of ARIPIPRAZOLE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
ORAL BIOAVAILABILITY PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966